Pharmaceutical Sector

Teva’s Bid for Mylan may Face Antitrust Issues Owing to Drug overlaps

Teva PharmaceuticalaOn Tuesday, Teva, the biggest generic drug manufacturer in the world made a $40 billion offer to buy Mylan NV. The company was also quick enough to signal that it was prepared to sell several of its overlapping assets in order to win the approval of the regulators.

Bristol-Myers to Acquire Privately Owned Drug Manufacturer Flexus Bioscience Inc.

Bristol-Myers to Acquire Privately Owned Drug Manufacturer Flexus Bioscience Inc.On Monday, the New York drug maker Bristol-Myers Squibb Co. said that it will acquire Flexus Bioscience Inc., which a privately owned drug manufacturer. The deal will be worth around $1.25 billion. The deal is an effort of Bristol-Meyers to add some promising cancer-fighting products into its list of offerings.

Valeant Pharmaceuticals International to Buy Salix Pharmaceuticals in a $10.1Billion All Cash Deal

Valeant Pharmaceuticals International to Buy Salix Pharmaceuticals in a $10.1Billion All Cash DealValeant Pharmaceuticals International is acquiring Salix Pharmaceuticals, the maker of gastrointestinal drugs in an all-cash deal which is worth approximately $10.1bn. The announcement came from both the companies on Sunday.

In a news release, the drug makers said that the deal for was approved by the boards of directors of both the companies.

Merck in Discussion with Cubist Pharmaceuticals for Acquiring the Company

Merck in Discussion with Cubist Pharmaceuticals for Acquiring the CompanyReportedly Merck & Co. is in discussion with Cubist Pharmaceuticals Inc. in order to buy the Lexington, Mass. based antibiotics maker. The deal is expected to be worth greater than $7 billion.

Allergan Sale to Actavis Cheers Investors Pushing Stocks to All Time High

Allergan Sale to Actavis Cheers Investors Pushing Stocks to All Time HighAllergan Inc., the maker of Botox is a company based in Irvine which started as a supplier of eye drops. With its growing range of health care products the company grew into a leading pharmaceutical company in the country. In a deal the pharma company agreed to be bought by Actavis, for $66 billion.

Third Quarter Earnings Report from CVS Health Corp. Surpass Analysts Expectations

Third Quarter Earnings Report from CVS Health Corp. Surpass Analysts ExpectationsOn Tuesday, CVS Health Corp. reported its third-quarter earnings that surpassed the expectations of the analysts. The main spike resulted from an increased use of specialty drugs. It helped to counterbalance the sales of the missing tobacco products on the shelves of the medicare company as it stopped selling all tobacco products this fall.

Pages